SBIR/STTR Research Award

Complex Dimensional in Vitro Human Skin Tissue Models for Scleroderma

Award identifier d8dc9cf1d9ce3707097486f18afeded3db4fe10c90639cd175cd2d6738a00301Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$225,000

Program and phase

SBIR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CELDARA MEDICAL, LLC
Proposal award date
2017-09-07
Contract end date
2018-08-31
UEI
MMVKQXZUBMQ7
Solicitation number
AR17-005
Topic code
NIAMS

Research abstract

Abstract Project Summary Scleroderma Systemic Sclerosis SSc is an autoimmune disease of unknown etiology that is characterized by vascular dysfunction fibrosis and inflammation One in three patients dies within years of diagnosis giving SSc the highest case fatality rate of any systemic autoimmune disease A lack of biologically relevant human SSc disease models has created a critical unmet need for more efficient preclinical drug screening models that can provide faster more cost effective ways of predicting the success or failure of drugs designed to treat SSc Recent advances in tissue engineering have resulted in D skin tissue based disease models that can provide in vitro models of SSc that closely mimic this disease in humans This will shorten the preclinical drug development timeline save animal lives reduce drug failure rates and inform FDA decision making for the development of new and effective disease therapeutics The development of D skin like tissue models that accurately recapitulate the SSc phenotype will be an important advancement over currently available monolayer D tissue cultures Bringing D skin models into Celdara Medical allows us to pair this promising in vitro system with our existing portfolio of SSc diagnostics and SSc fibrosis and cancer drug development efforts Beyond our immediate goals of optimizing and exploiting these well established D skin like tissues models for drug screening will advance complex tissue models for other organ systems such as lung By using multiple patient derived cell types we will optimize D tissues to establish proof of concept that robust SSc specific D tissue models can serve as preclinical drug screening platforms for new therapeutic agents for SSc Our aims are to optimize fabrication of SSc specific D tissue models harboring primary SSc derived fibroblasts macrophages M s and keratinocytes and To analyze the cell biology tissue properties and genomic similarity of D skin like tissues made from SSc cells against SSc patient skin biopsies Project Narrative The goal of this proposal is to fabricate and characterize D bioengineered skin like tissue models that mimic systemic sclerosis SSc using patient derived keratinocytes fibroblasts and macrophages ultimately for preclinical drug testing in a physiologically relevant system Development of robust predictive and cost effective skin models will improve the ability to test and identify the drugs most likely to be effective in SSc patients thereby providing a vast improvement for preclinical drug development

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

52 SBIR/STTR records share this UEI (2009–2025). Reported award amounts total $49,304,220. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.